Andrew Coney; Mitchell Walker; Brett Udland; Capital City Drug, LLC; And Axia Medical Solutions, LLC v. Prodigy Health, LLC

CourtCourt of Appeals of Texas
DecidedMarch 5, 2025
Docket03-24-00130-CV
StatusPublished

This text of Andrew Coney; Mitchell Walker; Brett Udland; Capital City Drug, LLC; And Axia Medical Solutions, LLC v. Prodigy Health, LLC (Andrew Coney; Mitchell Walker; Brett Udland; Capital City Drug, LLC; And Axia Medical Solutions, LLC v. Prodigy Health, LLC) is published on Counsel Stack Legal Research, covering Court of Appeals of Texas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Andrew Coney; Mitchell Walker; Brett Udland; Capital City Drug, LLC; And Axia Medical Solutions, LLC v. Prodigy Health, LLC, (Tex. Ct. App. 2025).

Opinion

TEXAS COURT OF APPEALS, THIRD DISTRICT, AT AUSTIN

NO. 03-24-00130-CV

Andrew Coney; Mitchell Walker; Brett Udland; Capital City Drug, LLC; and Axia Medical Solutions, LLC, Appellants

v.

Prodigy Health, LLC, Appellee

FROM THE 126TH DISTRICT COURT OF TRAVIS COUNTY NO. D-1-GN-24-000218, THE HONORABLE CATHERINE MAUZY, JUDGE PRESIDING

MEMORANDUM OPINION

In this trade secrets and unfair competition dispute involving two competing

pharmaceutical sales businesses, Andrew Coney, Mitchell Walker, Brett Udland, Capital City

Drug, LLC, and Axia Medical Solutions, LLC, (collectively, Appellants) appeal a temporary

injunction issued in favor of Prodigy Health, LLC. Appellants assert that the trial court abused its

discretion by issuing the temporary injunction because it is overbroad and lacks specificity in

violation of Texas Rule of Civil Procedure 683. For the following reasons, we will affirm in part,

reverse in part, and remand to the trial court. BACKGROUND 1

Prodigy’s business and Coney’s professional background

Prodigy is a nationwide specialty drug wholesaler. Andrew Coney, a pharmacist

turned entrepreneur, was the CEO of the drug wholesale company “Mockingbird and Cochran”

when discussions about a merger with Prodigy began in October 2021. Prodigy had strong

financials but sought to strengthen its sales team, and Mockingbird and Cochran had significant

outstanding debt but a successful and experienced sales force, including Coney. The merger

finalized in October 2022, and Mockingbird and Cochran integrated into Prodigy to bolster its

retail sales business, which sells medications to independent, non-chain pharmacies.

To remain employed following the merger, Coney signed an employment

agreement with Prodigy. 2 The agreement provided Coney would become Prodigy’s Director of

Products 3 in exchange for continued employment following the merger, a $200,000 annual salary

(which was $40,000 less than he made as Mockingbird and Cochran’s CEO), eligibility for

cash-based incentives or bonuses, a phantom unit award, 4 and benefits. It also included terms for

severance payments if Prodigy terminated Coney’s employment without cause or if Coney left

Prodigy for good cause or due to disability.

1 The background facts are derived from the undisputed evidence introduced at the hearing

on Prodigy’s application for temporary injunction, unless otherwise noted. 2 Coney’s employment agreement was contingent on the successful merger between Prodigy and Mockingbird and Cochran. 3 Coney later became Prodigy’s President of Retail Strategy. 4 A phantom unit award is an alternative to equity-based incentive plans and can be structured to mimic shares of stock. Phantom Stock Plan, Investopedia (June 20, 2024), http://www.investopedia.com/terms/p/phantomstock.asp. 2 In exchange, Coney agreed not to use or disclose Prodigy’s confidential

information and not to solicit Prodigy’s customers, vendors, or personnel during his employment

and for a one-year period following his termination from Prodigy’s employment. Coney’s

employment agreement also included a noncompetition provision. Under its terms, Coney agreed

that during his employment with Prodigy and for a one-year period after, he would not, “directly

or indirectly,” “(a) engage in conduct that is likely or probable to result in the disclosure of

proprietary information to a Competing Business;[ 5] and/or (b) be employed by, work as an

independent contractor for, own, receive or purchase a financial interest in, make a loan to, or

make a monetary gift in support of, any such Competing Business” within a 30-mile radius of a

defined territory, which included Prodigy’s corporate headquarters and each county in which

Coney worked on Prodigy’s behalf.

Mitchell Walker and Brett Udland also began working for Prodigy in October 2022,

but neither signed an employment agreement. However, Prodigy maintained that Walker,

Prodigy’s Director of Purchasing, and Udland, one of Prodigy’s retail sales representatives, did

sign Prodigy’s conflict of interest, ethical conduct, and confidential information policy, which

prohibits the disclosure of Prodigy’s proprietary and confidential information, including Prodigy’s

customer or employee information, “for personal gain or to compete against Prodigy.”

In mid-2023, several of Prodigy’s salespeople resigned after Prodigy changed its

commission structure per Coney’s recommendation. The former Prodigy employees cited the

commission change—which effectively reduced their compensation by approximately

5 The employment agreement defined “Competing Business” as a person or entity engaged

in the business of a wholesale pharmaceutical distributor that procures and distributes branded and generic drugs to independent pharmacies, hospitals, and clinics. 3 30 percent—as their reason for leaving. Walker also left Prodigy in September, as did Udland in

October. Coney resigned from Prodigy on December 1, 2023.

The other businesses: Capital City Drug and Axia

Meanwhile, in September 2022—before the merger completed but after Coney

received a draft of Prodigy’s proposed employment agreement—Coney created Capital City Drug,

LLC. He later testified he wanted to have a drug wholesale company in place to “hedge against

any risk of Prodigy firing [him.]” While Coney was still employed by Prodigy, Capital City Drug

sold an insulin product primarily in Puerto Rico. However, Coney attested that Capital City Drug

had largely paused its business by the end of 2023.

In July 2023, Amy Dang 6 purchased Axia, a California-based LLC that, shortly

before the sale, formally changed its stated business from selling dermatological products to selling

wholesale prescription drugs. In July and August, as Axia began its drug distribution business,

Walker and Coney assisted in its day-to-day operations, and Udland began contacting customers

on its behalf—all while still employed by Prodigy.

After Prodigy lost several members of its salesforce, at least seven of those

salespeople joined Axia, including Udland. And after Walker left Prodigy, he became Axia’s

COO. Coney is not formally employed by Axia but has provided consulting services. For their

work in 2023, Axia paid Walker $300,000 and Coney $125,000. Axia later paid Coney an

additional $475,000, which Coney described as compensation for his services assisting Axia

6 Amy Dang was engaged to Walker at the time of the temporary injunction hearing but is not a party to this appeal. 4 by recruiting staff, conducting interviews, working with warehouse integration, and

purchasing product.

In early December 2023, shortly after discovering that Coney, Walker, and Udland

(among others) had either formally joined or provided services to Axia, Prodigy sent cease and

desist letters to those three individuals, demanding that all three stop their “conduct constituting

misappropriation of trade secrets,” that Walker stop his “conduct constituting unauthorized

disclosure of Prodigy’s confidential information,” and that Coney stop his “conduct constituting

breach of contract.” Coney and Axia responded by suing Prodigy and its lender, Caprice Capital,

in California state court, seeking injunctive relief and a declaratory judgment that the conduct

Prodigy sought to restrain—including the obligations under Coney’s noncompetition agreement—

violated California law. The record in this appeal indicates that the California trial court denied

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Samlowski v. Wooten
332 S.W.3d 404 (Texas Supreme Court, 2011)
Sharma v. Vinmar International, Ltd.
231 S.W.3d 405 (Court of Appeals of Texas, 2007)
Southwest Research Institute v. Keraplast Technologies, Ltd.
103 S.W.3d 478 (Court of Appeals of Texas, 2003)
Interfirst Bank San Felipe, N.A. v. Paz Construction Co.
715 S.W.2d 640 (Texas Supreme Court, 1986)
Hitt v. Mabry
687 S.W.2d 791 (Court of Appeals of Texas, 1985)
Butnaru v. Ford Motor Co.
84 S.W.3d 198 (Texas Supreme Court, 2002)
Stocks v. Banner American Corp.
599 S.W.2d 665 (Court of Appeals of Texas, 1980)
Safeguard Business Systems, Inc. v. Schaffer
822 S.W.2d 640 (Court of Appeals of Texas, 1991)
T-N-T Motorsports, Inc. v. Hennessey Motorsports, Inc.
965 S.W.2d 18 (Court of Appeals of Texas, 1998)
National Collegiate Athletic Ass'n v. Jones
1 S.W.3d 83 (Texas Supreme Court, 1999)
Center for Economic Justice v. American Insurance Ass'n
39 S.W.3d 337 (Court of Appeals of Texas, 2001)
Computek Computer & Office Supplies, Inc. v. Walton
156 S.W.3d 217 (Court of Appeals of Texas, 2005)
Johnston v. American Speedreading Academy, Inc.
526 S.W.2d 163 (Court of Appeals of Texas, 1975)
Kulkarni v. BRAEBURN VALLEY WEST CIV. ASS'N, INC.
880 S.W.2d 277 (Court of Appeals of Texas, 1994)
Rugen v. Interactive Business Systems, Inc.
864 S.W.2d 548 (Court of Appeals of Texas, 1993)
Emerson v. Fires Out, Inc.
735 S.W.2d 492 (Court of Appeals of Texas, 1987)
Gonzales v. Zamora
791 S.W.2d 258 (Court of Appeals of Texas, 1990)
Miller Paper Co. v. Roberts Paper Co.
901 S.W.2d 593 (Court of Appeals of Texas, 1995)
Ricky D. Parker and James Myers v. Schlumberger Technology Corporation
475 S.W.3d 914 (Court of Appeals of Texas, 2015)
Villalobos v. Holguin
208 S.W.2d 871 (Texas Supreme Court, 1948)

Cite This Page — Counsel Stack

Bluebook (online)
Andrew Coney; Mitchell Walker; Brett Udland; Capital City Drug, LLC; And Axia Medical Solutions, LLC v. Prodigy Health, LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/andrew-coney-mitchell-walker-brett-udland-capital-city-drug-llc-and-texapp-2025.